JP2021521274A5 - - Google Patents
Info
- Publication number
- JP2021521274A5 JP2021521274A5 JP2021504589A JP2021504589A JP2021521274A5 JP 2021521274 A5 JP2021521274 A5 JP 2021521274A5 JP 2021504589 A JP2021504589 A JP 2021504589A JP 2021504589 A JP2021504589 A JP 2021504589A JP 2021521274 A5 JP2021521274 A5 JP 2021521274A5
- Authority
- JP
- Japan
- Prior art keywords
- pdl
- cancer
- pharmaceutical composition
- composition according
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024005463A JP2024054138A (ja) | 2018-04-12 | 2024-01-17 | がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382248 | 2018-04-12 | ||
| EP18382248.5 | 2018-04-12 | ||
| EP18382326 | 2018-05-14 | ||
| EP18382326.9 | 2018-05-14 | ||
| EP18382360.8 | 2018-05-25 | ||
| EP18382360 | 2018-05-25 | ||
| EP19382132 | 2019-02-22 | ||
| EP19382132.9 | 2019-02-22 | ||
| PCT/IB2019/000423 WO2019197903A1 (en) | 2018-04-12 | 2019-04-11 | Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024005463A Division JP2024054138A (ja) | 2018-04-12 | 2024-01-17 | がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521274A JP2021521274A (ja) | 2021-08-26 |
| JP2021521274A5 true JP2021521274A5 (enExample) | 2022-04-18 |
| JP7423598B2 JP7423598B2 (ja) | 2024-01-29 |
Family
ID=67060425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504589A Active JP7423598B2 (ja) | 2018-04-12 | 2019-04-11 | がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ |
| JP2024005463A Ceased JP2024054138A (ja) | 2018-04-12 | 2024-01-17 | がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024005463A Ceased JP2024054138A (ja) | 2018-04-12 | 2024-01-17 | がんの治療で使用するためのｌｉｆ阻害剤とｐｄ－１軸阻害剤との組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210130453A1 (enExample) |
| EP (1) | EP3774895A1 (enExample) |
| JP (2) | JP7423598B2 (enExample) |
| KR (1) | KR20210021287A (enExample) |
| CN (1) | CN112585164A (enExample) |
| AU (1) | AU2019251289B2 (enExample) |
| CA (1) | CA3096779A1 (enExample) |
| IL (1) | IL277918A (enExample) |
| MA (1) | MA52231A (enExample) |
| SG (1) | SG11202009966SA (enExample) |
| WO (1) | WO2019197903A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017381585B2 (en) * | 2016-12-19 | 2025-02-13 | Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats | Antibodies against LIF and uses thereof |
| KR20210008514A (ko) * | 2018-05-14 | 2021-01-22 | 메디뮨 리미티드 | Lif에 대한 항체 및 이의 투여 형태 |
| EP4069736A1 (en) * | 2019-12-04 | 2022-10-12 | MedImmune Limited | Antibodies against lif and uses thereof |
| JP7796032B2 (ja) * | 2020-03-11 | 2026-01-08 | パーデュー・リサーチ・ファウンデーション | 免疫調節活性を持つ化合物およびその治療的使用 |
| WO2023159152A2 (en) * | 2022-02-17 | 2023-08-24 | Immune-Onc Therapeutics, Inc. | Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU4231393A (en) * | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP2371860A1 (en) | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| WO2016040657A1 (en) | 2014-09-10 | 2016-03-17 | The Regents Of The University Of California | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES |
| EP3173483A1 (en) | 2015-11-27 | 2017-05-31 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Agents for the treatment of diseases associated with undesired cell proliferation |
| AU2017381585B2 (en) | 2016-12-19 | 2025-02-13 | Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats | Antibodies against LIF and uses thereof |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
-
2019
- 2019-04-11 WO PCT/IB2019/000423 patent/WO2019197903A1/en not_active Ceased
- 2019-04-11 AU AU2019251289A patent/AU2019251289B2/en not_active Ceased
- 2019-04-11 CN CN201980038348.0A patent/CN112585164A/zh active Pending
- 2019-04-11 US US17/046,599 patent/US20210130453A1/en not_active Abandoned
- 2019-04-11 JP JP2021504589A patent/JP7423598B2/ja active Active
- 2019-04-11 MA MA052231A patent/MA52231A/fr unknown
- 2019-04-11 SG SG11202009966SA patent/SG11202009966SA/en unknown
- 2019-04-11 EP EP19733546.6A patent/EP3774895A1/en not_active Withdrawn
- 2019-04-11 CA CA3096779A patent/CA3096779A1/en active Pending
- 2019-04-11 KR KR1020207032587A patent/KR20210021287A/ko not_active Ceased
-
2020
- 2020-10-11 IL IL277918A patent/IL277918A/en unknown
-
2024
- 2024-01-17 JP JP2024005463A patent/JP2024054138A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521274A5 (enExample) | ||
| JP2021008487A (ja) | 抗ｎｋｇ２ａ抗体を使用した治療計画 | |
| JP2018502051A5 (enExample) | ||
| JP2020536109A5 (enExample) | ||
| AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| US20070128204A1 (en) | Methods and compositions for inducing apoptosis in cancer cells | |
| RU2017107559A (ru) | Лечение раковых заболеваний с применением анти-nkg2a средств | |
| JP2020521478A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| KR102627372B1 (ko) | 후성유전적 조절제와 조합된 세마포린-4d 항체를 이용한 암의 치료 | |
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| JP2018535948A5 (enExample) | ||
| RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
| CN110022903B (zh) | Met抗体药物缀合物 | |
| JP2017113019A5 (enExample) | ||
| KR20230010221A (ko) | 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도 | |
| JP2022518232A5 (enExample) | ||
| JP2024510811A5 (enExample) | ||
| JP2023076596A5 (enExample) | ||
| JP7381555B2 (ja) | 腫瘍および／または転移の治療のための抗－ｈｇｆｒ抗体およびｈｅｇｆｒの組み合わせ | |
| Saadeh et al. | Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer | |
| JP2022502434A (ja) | がんの治療用の薬学的組合せ | |
| TW201828984A (zh) | 使用介白素-17(il-17)拮抗劑治療痤瘡的方法 | |
| WO2025094946A1 (ja) | 抗体又はその抗原結合性断片、がんの治療用キット、及びがんの治療用組成物 | |
| RU2024128344A (ru) | НОВЫЙ ИНГИБИТОР Mcl-1 И КОМБИНАЦИЯ Mcl-1 И МИМЕТИКА BH3, ТАКОГО КАК ИНГИБИТОР Bcl-2 |